Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
- 13 July 2017
- journal article
- practice guideline
- Published by Elsevier BV in Annals Of Oncology
- Vol. 28 (suppl_4), iv62-iv71
- https://doi.org/10.1093/annonc/mdx223
Abstract
Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy and represents 5%–7% of malignant lymphoma in Western Europe. The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently. MCL is more common in males than in women with a 3 : 1 ratio.Keywords
This publication has 56 references indexed in Scilit:
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 studyAnnals of Oncology, 2013
- High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trialLeukemia & Lymphoma, 2013
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'AdulteBlood, 2013
- Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499Journal of Clinical Oncology, 2012
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialThe Lancet Oncology, 2012
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood, 2010
- Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL NetworkJournal of Hematopathology, 2009
- Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell LymphomaTransplantation and Cellular Therapy, 2006
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkPublished by American Society of Hematology ,2005